Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company has already embarked upon significant expansion in Turkey
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
